The cyclin D1-cyclin-dependent kinase 4 (CDK4) complex is a key regulator of the transition through the G1 phase of the cell cycle. Among the cyclin/CDKs, CDK4 and cyclin D1 are the most frequently activated by somatic genetic alterations in multiple tumor types. Thus, aberrant regulation of the CDK4/cyclin D1 pathway plays an essential role in oncogenesis; hence, CDK4 is a genetically validated therapeutic target. Although X-ray crystallographic structures have been determined for various CDK/cyclin complexes, CDK4/cyclin D1 has remained highly refractory to structure determination. Here, we report the crystal structure of CDK4 in complex with cyclin D1 at a resolution of 2.3 Å. Although CDK4 is bound to cyclin D1 and has a phosphorylated T-loop, CDK4 is in an inactive conformation and the conformation of the heterodimer diverges from the previously known CDK/cyclin binary complexes, which suggests a unique mechanism for the process of CDK4 regulation and activation.
C
yclin-dependent kinases (CDKs) are a conserved family of proline-directed serine/threonine kinases that perform critical roles in regulating the stepwise progression through the eukaryotic cell cycle. The activity of CDKs is regulated through phosphorylation by other upstream kinases such as CDKactivating kinases (CAKs) and most significantly by interaction with cyclins (1, 2) . In turn, CDK/cyclin complexes are inhibited through the reversible binding of CDK inhibitors from the Cip/Kip and INK protein families and through the cyclical degradation of cyclins during the cell cycle (reviewed in ref. 3) .
CDK4 and CDK6 associate with the D-type cyclins (D1, D2, D3) and phosphorylate and inactivate the retinoblastoma (Rb) protein family members (p107, p130, pRb). Phosphorylation of pRb by CDK4/6 then leads to the derepression and activation of E2F target genes, including the E-type cyclins, which facilitate progression through the G 1 phase of the cell cycle.
Deregulation of the CDK4/cyclin D pathway has been identified in many cancers (refs. 4 and 5 and references therein and ref. 6) . Notably, most genetic alterations target specifically CDK4 or cyclin D1, whereas alterations in other CDKs and cyclins are far less common. The CDK4 gene is amplified in a high percentage of liposarcomas (7), and breast cancers frequently exhibit high cyclin D1 levels, either through genetic amplification of the gene or overexpression (8) . Translocation of cyclin D1 to the IgH promoter is a hallmark aberration in mantle cell lymphoma (9) . Cyclin D1 translocations can also be detected in many cases of multiple myelomas (10) . A mutation of CDK4 (Arg-24-Cys) that renders it refractory to inhibition by the tumor suppressor protein p16
INK4a has also been identified, and, similarly, deletion or mutation of the p16 INK4a gene results in defective CDK4 inhibition and dysregulated CDK4 activity (11) . Finally, genetic inactivation of p16INK4 is among the most frequent tumor suppressor mutations found in human cancers. Taken together, these data indicate that an unchecked or hyperactivated CDK4/cyclin D1 pathway may be responsible for enhanced cellular proliferation in cancers and imply that CDK4 is a promising target for the development of anticancer therapies (reviewed in ref. 12) .
The molecular basis of CDK activation has been the focus of many studies using cellular, biochemical, and structural approaches (reviewed in ref. 3) . Maximal CDK activation requires both binding of a cognate cyclin and phosphorylation of residues within the CDK T-loop, and X-ray crystallographic studies of various CDKs and CDK/cyclin complexes have identified the conformational movements associated with CDK activation (13) (14) (15) (16) . Activation is characterized by movement of the ␣C-helix such that a highly-conserved glutamate residue moves into the kinase active site and an arginine residue is positioned to interact with the phosphothreonine of the T-loop. The T-loop moves away from the active site and is held in position by interactions with the cyclin and interaction of the phosphothreonine with a cluster of arginine residues.
Despite the significant interest in CDK4 its structure determination has eluded numerous efforts from many groups. Here, we describe the crystal structure of human CDK4 in complex with a cognate D-type cyclin.
Results
Coexpression of CDK4 and cyclin D1 in insect cells yielded an active, but heterogeneously-phosphorylated, complex that did not crystallize. To facilitate crystallization of the CDK4/cyclin D1 complex a number of modifications were required (see SI Text). The C-terminal 24 residues of cyclin D1, containing a polyglutamate region and phosphorylation site, were removed to reduce predicted conformational f lexibilty and phosphoheterogeneity. Residues 42-48 of CDK4, consisting of 7 glycine residues, were replaced with the equivalent GEEG sequence from CDK6. Combining these changes gave a small, but significant, increase in the thermal stability of the complex and proved crucial for obtaining crystals that diffracted to high resolution. In different complexes, the site of CDK4 T-loop phosphorylation (Thr-172) was either phosphorylated (T172Ph), changed to alanine (T172A, phospho knockout) or changed to aspartate (T172D, phosphomimetic) (see Fig. S1 ). The constructs and their relative enzymatic activities are described in Table 1 . All constructs that yielded crystals diffracting to high resolution gave structures that were highly homologous to each other. In each case the N-terminal 20 residues of cyclin D1 were disordered, thus a new construct was generated in which residues 1-14 of cyclin D1 were removed. This process resulted in a complex that crystallized readily from a variety of conditions, but did not result in higher-resolution data. Because all of the structures were equivalent to each other the key features of the structure will be described for the complex that gave the highest-resolution data (CDK4 T172D, Gly-42-Glu-43Ј-Glu-44Ј-Gly-48/cyclin D1 ).
CDK4 has the typical bilobal structure seen in other kinases, comprising a 5-stranded ␤-sheet, N-terminal domain (residues 1-96), in which helix-␣C (sequence PISTVRE in CDK4 and PSTAIRE in CDK2) is packed against the ␤-sheet, and a predominantly helical C-terminal domain (residues 97-303) (Fig. 1A) . The ATP binding site is located in the cleft between the domains. Although this structure is unliganded, it suggests that only minimal conformational rearrangement of residues Asp-99, Asp-140, Lys-142, and Tyr-17 would be necessary to accommodate ATP binding in the active site.
The main-chain density of the T-loop for the Thr-172-Ala and Thr-172-Asp substitutions is well defined, but the side-chain density is poor in this region (residues170-192). In the structure obtained with a phosphorylated T-loop there is no density for residues 170-175. The presence of CDK4 phosphorylated on Thr-172 was confirmed by mass spectrometry of dissolved crystals (see SI Text). However, in each case the T-loop has a short section of well-defined ␣-helical structure (residues 161-171) and is in the ''loop in'' conformation more characteristic of an ''inactive'' CDK (Fig. 1B) . This ensemble of structures suggests that for CDK4 neither phosphorylation of the T-loop nor binding to its cognate cyclin is sufficient to trigger the conformational change typically associated with a fully-activated CDK, although enzymatic data demonstrate that the phosphorylated complex used to obtain the structure has robust activity against Rb protein substrate (see below and Table 1 ). Our data and lambda-phosphatase incubation studies (see Fig. S2 and Nick Brown, Oxford University, Oxford, United Kingdom, personal communication) suggest that the phosphate on the T-loop is solvent accessible and that T-loop phosphorylation is required for enzymatic activity.
The cyclin D1 molecule has a classical double cyclin box domain fold, comprising 11 ␣-helices ( Fig. 2A) . Intercomparison of cyclin D1 with the structures of other cyclins (A, E, K, M, vCyc) ( Fig. S3 and Table S1 ) reveals the expected general equivalence between secondary structural elements. Cyclin D1 is known to contain 2 Rb binding sites (17) comprised of an N-terminal LxCxE consensus motif and a peptide recruitment site. The cyclin D1 structure exhibits N-terminal disorder, so the LxCxE motif cannot be visualized. Comparison of the cyclin D1 structure with cyclin A suggests that the peptide recruitment site, which recognizes a consensus RxL motif, is conserved in cyclin D1 and should be capable of comparable peptide binding (18) (Fig. S4D ). This observation has been confirmed by peptide binding studies.
The most striking feature of the CDK4/cyclin D1 complex is the interaction between the 2 molecules. Although cyclin D1 has engaged with the ␣C-helix (PISTVRE) of CDK4, the helix has not undergone the conformational switch associated with CDK activation, as observed in all other CDK/cyclin binary complexes solved to date (Fig. 2) (14) (15) (16) 19) . Instead the CDK4 structure more closely resembles the structures of inactive and non-cyclinbound CDK2 and CDK7 (Fig. 1B and Table S2 ) (13, 20) , or an INK-inhibited CDK6, particularly the CDK6/p19 INK4d structure (21) . Furthermore, the CDK4 T-loop is stabilized in an inactive conformation caused by interactions with both the N-and C-terminal lobes of the kinase (Fig. 1B) . The residues immediately following the Asp 158 -Phe-Gly 160 (DFG) motif have condensed into a helix (Leu 161 -Leu 171 ) that is stabilized by interactions with ␣C-helix, ␤4-strand, ␤6-strand, and the apex of the P-loop (Fig. 1) . Again, broadly similar T-loop architectures are observed with CDK7, where the T-loop is phosphorylated (Fig.  1B) , and with CDK6 in the CDK6/p19 INK4d complex. The interconnectivity of these secondary structural elements in The relative activities of the constructs were determined by measuring the initial rates of reaction for each construct in the presence of 2 m⌴ ATP. Rates were then normalized relative to the wild-type construct. CDK4 EE represents CDK4 with residues 42-48 replaced by Gly 42-Glu43Ј-Glu44Ј-Gly48, the sequence found in CDK6. Ph represents phosphorylation of the indicated residue. CDK4 indicates how activation signals could be transmitted throughout the kinase upon movement of the ␣C-helix.
Although the CDK4 ␣C-helix appears to have been engaged and bound by cyclin D1 in a comparable fashion to other heterodimeric complexes, the C-lobe of CDK4 has not rotated to maximally associate with the cyclin N terminus. This lack of rotation reduces the buried surface area of the CDK4/cyclin D1 interface (2,334 Å 2 ) relative to the majority of other CDK/cyclin binary complexes (typically in the 3,000-4,000 Å 2 range; Fig. 2 , Table S3 , and Fig. S5 ). This conformation of the CDK4/cyclin D1 complex is observed in all of our structures, even though they were crystallized under a diverse set of conditions. In terms of relative subunit disposition and CDK/cyclin interface, the most analogous structures are the ternary complex comprising CDK6/ cyclin K bound to the protein inhibitor p18
INK4c (22) (Fig. 2B ) and the binary CDK9/cyclinT1 structure (19) (Fig. 2C) . INK4c binding is distal to the CDK6/cyclin K interface and induces a rotation of the CDK6 N-terminal lobe relative to the C-terminal domain. This rotation distorts the CDK6 active site, induces the T-loop to adopt a distinct, inhibited conformation, and drives the ␣C-helix into an inactive, or ''out,'' configuration. These CDK6 conformational changes also remodel the CDK6/cyclin K interface such that cyclin K only engages with the CDK6 ␣C-helix and the N-terminal lobe (Fig. 2B) , which is highly reminiscent of what is observed in the CDK4/cyclin D1 structure (Fig. 2 A) . Inspection of the CDK4/cyclin D1 crystal packing reveals an absence of lattice contacts capable of mimicking INK binding, thereby reducing the possibility of the conformation of the complex being an artifact of crystallization (Fig. S6 ). In the CDK9/cyclin T1 structure cyclin binding drives the ␣C-helix into an active, in, conformation; however, the relative disposition of the cyclin and CDK and the buried surface area of the complex deviate significantly from other activated CDK/cyclin heterodimers (Fig. 2C, Fig. S5 , and Table S3 ). Cyclin T1 is pivoted away from the CDK by Ϸ26°, reducing the buried surface area to Ϸ60% of that observed in the CDK2/cyclin A complex (19) .
Discussion
The CDK4/cyclin D1 structure suggests that there may be 2 general mechanisms for CDK/cyclin regulation. The first is inhibition of CDK/cyclin complexes, through the binding of proteinaceous inhibitors. This would apply to CDK/cyclin complexes that spontaneously adopt an active conformation upon heterodimerization (22) . The second mechanism would require activation of CDK/cyclin heterodimers, such as CDK4/cyclin D1, that do not spontaneously remodel into an active conformation upon association. This activation would be via cofactor (e.g., Cip/Kip proteins) and/or substrate binding.
To facilitate crystallization, all 4 of our CDK4/cyclin D1 complexes contain CDK4 in which the loop [Gly-42-(Gly) 5 -Gly-48, Gly 7 ] immediately preceding the ␣C-helix has been truncated and modified to the equivalent sequence found in CDK6 [Gly-42-Glu-43Ј-Glu-44Ј-Gly-48, GEEG) (Fig. 3A ). An intercomparison of the structure of this modified loop in CDK4/cyclin D1 with the equivalent loops in CDK2/cyclin A and CDK6/vCyc reveals a high degree of structural parity in this region (Fig. S4 ). In all 3 systems the loop conformation is stabilized by main-chain hydrogen bonds from the loop to a highly-conserved lysine (Lys D1 112) and glutamate (Glu D1 141) on the cyclin. The glutamates from the engineered CDK4 GEEG replacement mimic the interactions formed by the identical loop in CDK6 and help to further stabilize this region of the CDK4/cyclin D1 structure. Although we cannot rule out the possibility that the introduced substitutions have stabilized an intermediate conformational state, Coleman et al. (23) have demonstrated that truncation of the CDK4 Gly 7 loop does not perturb either cyclin D1 or p16 binding. The enzymatic activity of phosphorylated CDK4 GEEG in complex with truncated cylin D1 was comparable to that of CDK4/cyclin D1 in which the Gly 7 loop had not been modified ( Table 1 ), suggesting that the crystallized complex is structurally and functionally equivalent to the wild-type complex. This assertion is further supported by the structure of native CDK4 in complex cyclin D3 described by Takaki et al. (40) in this issue, which does not contain substitutions in this region but yields a homologous complex structure. Furthermore, the interactions observed in this region are consistent with previous studies (24) (25) (26) that have shown that mutation of Lys D1 112 or Lys D1 114 ( Fig. 3 ) results in cyclins that are defective in their ability to activate and/or bind CDK4. The Lys D1 112-Glu mutation would disrupt the stabilizing H-bond interactions with the ␤4-␣C helix loop and Glu D1 141. The Lys D1 114-Glu mutation would introduce an additional, potentially destabilizing, negative charge into the acidic environment formed by Glu D1 74-Glu-Glu D1 76 and Asp D1 159 and Table S2 and . The CDK6 T-loop has a loop out conformation that is characteristic of a fully-activated CDK, as is the ␣C-helix conformation that is rotated to an in position. The buried surface area of the CDK6/vCyclin interface is 3,974 Å 2 . This is a high value for CDK/cyclin binary complexes and helps to explain how the viral cyclin is able to activate the CDK6 even in the absence of phosphorylation of the CDK6 T-loop.
Glu D1 162 (Fig. 3B ). This mutation, through its proximity to the CDK/cyclin interface and ␣C-helix, could again disrupt complex activation. The activation and kinetics of the CDK4/cyclin D1 complex differ from other CDK/cyclin complexes. p50 cdc37 and Hsp90 have been shown to be important for CDK4 maturation (ref. 27 and references therein), and members of the (Cip/Kip/INK) protein families can modulate the assembly, stability, activity and correct nuclear localization of CDK4/cyclin D complexes (1, (28) (29) (30) (31) (32) (33) . Consistent with these data it has been shown that active CDK4/CycD1 complex cannot be readily reconstituted by mixing recombinant CDK4 and cyclin D (2). Unlike CDK2/cyclin A (34), CDK4 does not appear to spontaneously activate when bound to cyclin D and exhibits ordered addition kinetics (35, 36) . Phosphorylation studies using peptidic or Rb-protein substrates reveal a low specific activity of CDK4/cyclin D1 versus peptides and a modulation of the enzymatic K m for ATP (36) (37) (38) (39) . On the basis of these data and our structure it can be speculated that protein substrate and/or cofactor binding may be necessary to promote remodeling of the CDK4/cyclin D1 interface and ␣C-helix into active conformations. The observation that deletion of the N-terminal region of cyclin D1 resulted in a large reduction in catalytic activity of the complex perhaps suggests that this region may play a role in this remodeling process (see SI Text). It can also be speculated that the CDK/cyclin conformation of the remodeled CDK4/cyclin D1 complex may more closely mimic the conformation of CDK9/cyclin T1 rather than CDK2/cyclin A.
We propose that the CDK4/cyclin D1 complex presented here represents a stable, and previously structurally uncharacterized, intermediate state in which the CDK is potentiated for final activation. It is distinct from most other CDK/cyclin complexes in which cyclin binding triggers spontaneous remodeling and activation of the CDK. Furthermore, complete activation of the CDK4/cyclin D1 complex may only occur with Cip/Kip ternary complex formation, nuclear translocation, substrate recruitment/binding, and T-loop phosphorylation. This mechanism would provide an elegant means for tightly regulating CDK4 activity until the CDK4/cyclin D1 complex was correctly localized within the cell and productively bound to substrate.
Materials and Methods
IMAGE Clones. IMAGE consortium cloneID MGC2316 (cyclin D1) and IMAGE consortium cloneID MGC19704 (CDK4) (Geneservice Ltd.) were used for initial construct generation.
Protein Purification. CDK4 and cyclin D1were expressed in SF21 insect cells and harvested 72 h after infection. After sonication and clarification, the complex was purified by using Ni-NTA agarose batch binding, HitrapQ FF ion exchange chromatography, and gel filtration on a Sephacryl S200HR(26/60) column. The purified complex was typically concentrated to 10 -12 mg/mL in 20 mM Tris⅐HCl (pH 8), 10% glycerol, 150 mM NaCl, and 5 mM DTT for crystallization. All work was carried out at 4°C. Table S4 .
Measurement of CDK Enzyme Activity. CDK enzyme activity was measured by using an ELISA format. Briefly, plates were coated with GST-pRb 769 -921 (purified as described in ref. S4 ) the apex of the loop is stabilized by hydrogen bonds from the loop main chain to a highly-conserved lysine (Lys D1112) and glutamate (GluD1141) on the cyclin. The second glutamate (Glu K444Ј) from the GEЈEЈG insertion mimics the interactions formed by the glutamate in the CDK6 structure. The loop is further stabilized by intramolecular H-bonds, which are not observed in either the CDK2 or CDK6 structures. A cyclin D1 Lys D1112-Glu mutation results in aberrant CDK4/cyclin D1 complex assembly and activation. (B) Residues in the vicinity of cyclin D1 (orange) Lys D1114. The LysD1114 -Glu mutation results in defective CDK4/cyclin D1 complex formation. Lys D1114 sits within an acidic environment formed by Glu D174, GluD175, GluD176, AspD1159, and GluD1162. It would be anticipated that introduction of an additional negative charge into this environment would be highly destabilizing and significantly perturb correct CDK/cyclin association. Fig. S1 . Coexpression of full-length, CDK4 (residues 1-303), with a C-terminal hexa-histidine tag, and cyclin D1 (residues 1-295) in insect cells yielded an enzymatically-active complex that had heterogeneous phosphorylation of both CDK4 and cyclin D1, and failed to crystallize. Introduction of T172A (CDK4) and T286A (cyclin D1) substitutions yielded a nonphosphorylated complex that also failed to crystallize. Subsequently cyclin D1 was C-terminally truncated (CycD1 ) to remove the Thr-286 phosphorylation site and flexible polyglutamate PEST region, and the hepta-glycine loop of CDK4 (residues 42-48) was replaced with Gly 42 -Glu 43 Ј-Glu 44 Ј-Gly 48 (CDK4 EE ), the sequence found in CDK6. See Fig. S1 .
Supporting Information
The CDK4 EE T172A/CycD1 1-271 complex yielded crystals diffracting to 2.8 Å and enabled a molecular replacement structure solution (see below). Novel crystallization conditions were also identified for CycD1 in complex with a phospho-mimetic construct CDK4 EE T172D and with a CDK4 construct containing phosphorylated T172 (CDK4 EE T172Ph). Data were collected to 2.3-and 2.9-Å resolution, respectively, for each of these complexes. The phosphor ylation state of cr ystallized CDK4 EE Ph/CycD1 1-271 was confirmed by LC/MS analysis of dissolved complex crystals. All 3 of the complexes yielded equivalent structures. In all of these structures the N-terminal region of cyclin D1 was disordered. Thus a further truncation was designed (CycD1 ) that, in combination with CDK4 EE T172A, produced a complex that crystallized readily, even in the absence of precipitant, yielding a 2.5-Å resolution structure.
Protein Purification. CDK4 EE (1-303/His 6 )/CycD1 1-271 was expressed in SF21 insect cells and harvested 72 h after infection. After sonication and clarification, the complex was purified by using Ni-NTA agarose batch binding, HitrapQ FF ion exchange chromatography, and gel filtration on a Sephacryl S200HR(26/ 60) column. The purified complex was typically concentrated to 10-12 mg/mL in 20 mM Tris⅐HCl (pH 8), 10% glycerol, 150 mM NaCl, 5 mM DTT for crystallization. All work was carried out at 4°C. (2) generated consistent rotation function (RF) solutions by using a variety of cyclin alignments, models, and ensembles. A weak RF solution was found for CDK4 by using the C-terminal domain of CDK6 (extracted from PDB ID code 1BLX, 1.9Å) as a search model, but no translation function (TF) solutions were found for all of the CDK and cyclin models tested. Data twinning tests proved negative and so TF solutions were sought in all 7 other orthorhombic space groups. P2 1 2 1 2 1 yielded excellent TF solutions for cyclin D1 and weak TF solutions for the CDK C-terminal domain model. Extensive attempts to find solutions for the CDK4 N-terminal domain failed. The spacegroup ambiguity was identified as being attributable to anisotropic mosaicity that had lead to an overlap of closely separated (h,0,Ϫl), (h,0,0) and (h,0,l) spots. The CDK4/CycD1 crystals are plate-like and it is likely that the long c-axis is perpendicular to the plate and that the anisotropic mosaicity is caused by warping of the plate. The P2 1 2 1 2 1 molecular replacement solutions revealed new helical density proximal to the cyclin, which was thought to correspond to the kinase ␣1-helix. The validity of this solution was, however, questioned as it implied a radically different relative disposition of the CDK and cyclin subunits, as compared with other CDK/cyclin complexes. An independent molecular replacement solution was sought and found, but simply confirmed the previously identified solution. Again the N-terminal domain of the kinase could not be identified.
Because conventional molecular replacement had failed to locate the CDK4 N-terminal domain, an attempt was made to identify its location by using real space search methods. An ESSENS (3) search using polyAla search models constructed from the CDK6 N-terminal domain from PDB ID code 1BLX and CDK6 ␣1-helix from PDB ID code 1BLX yielded a plausible solution. Rigid body refinement of the hybrid model comprising the cyclin D1 N-and C-terminal domains, CDK4 N-terminal domain ␤-sheet polyAla model, CDK4 C-terminal domain (CDK6 molecular replacement solution), and polyAla ␣1-helix model gave R ϭ 0.544.
At this time MIR data became available, although both the ''new'' native and derivative data sets were nonisomorphous with the original native. Model phased heavy-atom difference Fourier and MLPHARE (4) gave a 4-site solution for a PCMBS 3.7-Å derivative, although it had inadequate phasing power and resolution to enable an independent SIR(AS) map. Phase combination with the molecular replacement model phases gave a map of sufficient quality to enable initial model building. Subse-quently, the original, higher-resolution, native dataset was used for iterative model rebuilding and refinement.
It proved possible to position the majority of main-and side-chain atoms in cyclin D1, but side-chain density was generally poor within CDK4. The difference in the quality of the electron density for the CDK4 and cyclin D1 subunits correlated with significantly elevated B factors in CDK4, with the exception of the ␣1-helix. Simulated annealing did not improve map quality. Initially the structure was manually rebuilt and refined by using Refmac (5), but Buster and autoBuster were used as refinement packages in the later stages of the refinement (6).
Data collection and refinement statistics for the four structures determined are listed in Table S4 .
Measurement of CDK Enzyme Activity. CDK enzyme activity was measured by using an ELISA format. Briefly, plates were coated with GST-pRb 769 -921 (purified as described in ref. Plates were then washed with TBST and incubated for 1 h with the primary antibody (CDK4: anti-p-Rb Serine 780, New England Biolab; Cdk2: p-Rb Threonine 821, Biosource) diluted in Superblock. Excess antibody was washed off and plates were then incubated with secondary antibody (alkaline phosphatase-linked anti-rabbit; New England Biolab) for another hour. After removal of excess secondary antibody, plates were developed by using the Attophos system (Promega) and the fluorescence was read on a Spectramax Gemini plate reader (Molecular Devices) at excitation 450 nm and emission 580 nm.
The relative activities of the constructs were determined by measuring the initial rates of reaction for each construct in the presence of 2 m⌴ ATP. Rates were then normalized relative to the wild-type construct.
rmsd Calculations for Kinase and Cyclin Overlays. PDB files were superposed by using C␣ atoms in KFIT (software from I.J.T.). Atom pairs separated by Յ2 Å were included in calculations. The superposed cyclins are shown in Fig. S3 . rmsd values for the cyclin and kinase superpositions are tabulated in Table S1 and  Table S2 respectively.
Buried Surface Area Calculation and Contact Surfaces. Buried surface areas (Table S3) were calculated by using MAXBSA (software from I.J.T.). Contact surfaces were generated by using AREAIMOL (4) with a 1.4-Å probe radius and are shown in Fig. S5 . LC/MS of Dissolved CDK4EET172Ph/CycD11-271 Crystals. Three crystals were diluted from 1.5 M phosphate to water in 3 steps to a final volume of 15 L. All crystalline material had dissolved after 1 h at 4°C at which point the sample was diluted to 75 L in 2% formic acid and analyzed by LC/MS. LC Method. The method involves a 25-l injection, 23-min run with a 13-min linear gradient from 0% B to 100% B. Solvents were: A -0.2% formic acid, B -60% isopropanol/0.2% formic acid. LC column was a Phenomenex Luna C8 150 ϫ 3 mm. Flow rate was 0.2 mL/min, column compartment temperature was 60°C, and UV detection was at 220 nm. Eluate was fed directly in to the source of a Bruker Daltonics MicroTOF MS. Each injection was internally calibrated with Agilent Tunemix from m/z ϭ 322 to 2,721.
Two adjoining peaks were observed at retention time ϭ 15-16 min in both the UV and the total ion chromatogram traces. The first peak contained a major species mass 34,516.6 Da, corresponding to acetylated, monophosphorylated CDK4 EE T172Ph with Ϸ14% of a second species, mass 34,435.9 Da, corresponding to nonphosphorylated CDK4 EE T172. The second peak contained approximately equal amounts of 2 species mass 30,995.0 and 31,075.0 Da, corresponding to nonphosphorylated and monophosphorylated CyclinD1 .
Sequences of CDK4 and Cyclin D1. For amino acid sequences of wild-type CDK4 and CyclinD1 (upper sequence) see Fig. S1 . For reference the sequences for the mutated and truncated CDK4 and cyclin D1 constructs are listed below the wild-type sequences.
Discussion of Role of Cyclin N Terminus. We present structures for a CDK4/cyclin D1 complex containing full-length cyclin D1 and also cyclin D1 that has a 15-aa N-terminal deletion. Both heterodimeric complexes are structurally equivalent, suggesting that the cyclin D1 N terminus alone cannot trigger a reconfiguration of the CDK4/cylcin D1 complex.
The CDK4/cyclin D1 complex containing truncated D1 cyclin has substantially reduced catalytic activity compared with the wild-type complex ( Table 1 ). The reasons for this are not known. The N terminus of the cyclin contains a LxCxE Rb substrate binding motif. Deletion of this motif may alter the substrate specificity and/or activity of the CDK/cyclin complex (19) (20) (21) . Activity was determined by using an ELISA format with antibodies against phospho-Ser-780 of a truncated Rb construct (GST-Rb 769-921). The kinase could potentially still have catalytic activity versus Rb, but with reduced phosphorylation of the site being probed (19) (20) (21) . It could also be argued that the use of truncated Rb substrate may subtly modulate the selectivity/activity profile of the CDK/cyclin complex. Kinase activity may be genuinely reduced if the cyclin D1 N-terminal deletion has an impact on recruitment, binding, and orientation of the truncated Rb substrate (19) (20) (21) . Mutational studies with the K-cyclin from herpesvirus (related to the D-type cyclins) have shown that the cyclin N terminus can modulate kinase substrate specificity (22) . It should, however, be noted that the cyclin D1 LxCxE motif is not conserved in the viral cyclins.
The CDK4/cyclin D1 complexes presented have a similar overall conformation to the CDK9/cyclin T1 complex (18) . The first 9 N-terminal amino acids of cyclin T1 are disordered and solvent exposed. Structures of CDK6 in complex with the vCyclin from herpesvirus saimiri, again related to the D-type cyclins, reveal the CDK6/vCyc complex to be in a fully active conformation (8) . A similar active conformation is also observed in the structure of CDK2 complexed with a viral M-cyclin (16) . In both structures the N terminus of the viral cyclin contacts and stabilizes the T-loop of the kinase. It is is, however, difficult to draw direct comparisons between the role of the cyclin D1 N terminus in our structures and the role of the V/M-cyclin N-termini because of the complexes adopting fundamentally different conformations and the lack of sequence conservation at the cyclin N-termini. See references in Tables S1 and S2 for kinase and cyclin overlays section. 
